Search Results - "Shapiro GI"

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.

Authors: Lorusso P Shapiro GI Hurwitz H et al.

Source: Cancer Chemotherapy & Pharmacology. Dec2011, Vol. 68 Issue 6, p1377-1385. 9p.

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Authors: McKay RR Xie W Ajmera A et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jun 20; Vol. 44 (18), pp. 1709-1719. Date of Electronic Publication: 2026 May 07.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study; Comparative Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Authors: Merriam P Morrow JJ Mazzola E et al.

Source: Nature medicine [Nat Med] 2026 Jun; Vol. 32 (6), pp. 2191-2200. Date of Electronic Publication: 2026 May 26.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.

Authors: Cheng X Zhang Y Qian C et al.

Source: Nature communications [Nat Commun] 2026 May 04. Date of Electronic Publication: 2026 May 04.

Publication Type: Journal Article

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Authors: Huffman BM Diossy M Yurgelun MB et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 01; Vol. 32 (9), pp. 1666-1677.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Authors: Jacob S Mayer EL Kacik N et al.

Source: ESMO open [ESMO Open] 2026 Apr; Vol. 11 (4), pp. 106063. Date of Electronic Publication: 2026 Mar 10.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Authors: McKay RR Xie W Ajmera A et al.

Source: Cancer [Cancer] 2026 Jul 01; Vol. 132 (13), pp. e70496.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.

Authors: Nakashoji A Bhattacharya A Ozawa H et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2025 Apr 26; Vol. 11 (1), pp. 39. Date of Electronic Publication: 2025 Apr 26.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Authors: Fassl A Palacios Espinoza M Butter D et al.

Source: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2026 Mar 24; Vol. 123 (12), pp. e2522872123. Date of Electronic Publication: 2026 Mar 18.

Publication Type: Journal Article

Journal Info: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 Inhibitors.

Authors: Cecchini D Nigam A Tang M et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2026 Mar 23. Date of Electronic Publication: 2026 Mar 23.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial.

Authors: Doroshow DB Shapiro GI Do K et al.

Source: Cancer [Cancer] 2026 Mar 15; Vol. 132 (6), pp. e70332.

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.

Authors: Li BT Gandhi L Ravichandran V et al.

Source: Clinical lung cancer [Clin Lung Cancer] 2026 Mar; Vol. 27 (2), pp. 214-226.e5. Date of Electronic Publication: 2025 Oct 01.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.

Authors: Dumbrava EE Shapiro GI Parikh AR et al.

Source: The New England journal of medicine [N Engl J Med] 2026 Feb 26; Vol. 394 (9), pp. 872-883.

Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

A Phase Ib Study of Sapacitabine and Olaparib in Patients with BRCA1/2-Mutated Metastatic Breast Cancer.

Authors: Lynce F Graham N Kochupurakkal BS et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 Feb 04; Vol. 32 (3), pp. 489-500.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial.

Authors: Cecchini M Pilat MJ Uboha N et al.

Source: Cancer [Cancer] 2025 Feb 15; Vol. 131 (4), pp. e35755.

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Authors: Gounder M Johnson M Heist RS et al.

Source: Nature communications [Nat Commun] 2025 Jan 06; Vol. 16 (1), pp. 423. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Authors: Walton SA Kim JJ Paoloni F et al.

Source: JCO precision oncology [JCO Precis Oncol] 2025 Dec; Vol. 9, pp. e2500526. Date of Electronic Publication: 2025 Dec 05.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer via Induction of miR-34a-5p.

Authors: Liu R Wang X Branigan TB et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 5096-5110.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors.

Authors: Zhu G Asada S Nguyen H et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Nov 21. Date of Electronic Publication: 2025 Nov 21.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

Authors: Villaruz LC Jin J Wang H et al.

Source: Cancer [Cancer] 2025 Nov 01; Vol. 131 (21), pp. e70157.

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE